| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02422940 Details | 2019-01-22 Interventional | 3 | 294 | 4-Aminopyridine Ischemic Stroke Post-ischemic S… | - - | |||
| NCT02205398 2014-000579-20 Details | 2019-01-22 Interventional | 1 | 13 | Cetuximab Carcinoma, Squa… Colorectal Neop… Squamous Cell C… Metastatic Colo… Squamous Cell C… | - - | |||
| NCT03808168 Details | 2019-01-18 Interventional | 2 | 0 | Nivolumab Uterine Cervica… Cervix Uteri--D… | FDA has withdrawn the IND application- requesting protocol changes - | |||
| NCT02148367 Details | 2019-01-18 Interventional | 2 | 0 | Epoetin Alfa Brain Injuries Brain Injuries,… Traumatic Brain… | Publication of recent trials showing no effect of EPO in TBI. - | |||
| NCT00499733 Details | 2019-01-18 Interventional | 1 | 19 | Cyclophosphamid… Cancer | The study was terminated per PI decision. - | |||
| NCT01198379 Details | 2019-01-17 Interventional | 4 | 0 | Aspirin Kidney Failure,… End-Stage Renal… | No participants enrolled - | |||
| NCT01912378 Details | 2019-01-16 Interventional | 1 | 0 | Oxytocin Autistic Disord… Autism Disorder | unable to launch the study due to lack of participation with Autism Clinic - | |||
| NCT03803163 Details | 2019-01-14 Interventional | 1 | 20 | Treprostinil Healthy Volunte… | Discontinued early due to local tolerance expectations not being met. - | |||
| NCT02975921 Details | 2019-01-11 Interventional | 4 | 0 | Povidone Povidone-Iodine Heart Failure Pleural Effusio… Pleural Effusio… Malignant Pleur… Pleural Effusio… Pleural Effusio… Pleural Effusio… Pleurodesis | The site decided not to proceed with the protocol. - | |||
| NCT02407314 Details | 2019-01-11 Interventional | 4 | 26 | Aspirin Ticagrelor Peripheral Arte… Peripheral Vasc… | AZ discontinued study - | |||
| NCT02220088 Details | 2019-01-11 Interventional | 2/3 | [7 Refs] | 79 | Fluorouracil Leucovorin Oxaliplatin Sorafenib Carcinoma, Hepa… Hepatocellular … | protocol violation - | ||
| NCT03324243 Details | 2019-01-10 Interventional | 2 | 0 | Crenolanib Cytarabine Fludarabine Leukemia, Myelo… Relapsed/Refrac… | Withdrawn: Study halted prior to enrollment of first participant - | |||
| NCT02657447 2013-003908-39 Details | 2019-01-10 Interventional | 1 | 0 | 1,4,7,10-tetraa… Lymphoma Lymphoma, Non-H… Non-Hodgkin Lym… | Study is no longer relevant - | |||
| NCT02109445 2013-005574-21 Details | 2019-01-10 Interventional | 2 | 3 | Albumin-Bound P… Gemcitabine Nirogacestat Paclitaxel Adenocarcinoma Metastatic Canc… | The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No
safety/efficacy concerns were behind the reason of trial termination Due to early termination of the study, only 3 participants were enrolled. Phase 2 was not carried out. As such, there is limited data for Phase 1 and no data for Phase 2. | |||
| NCT01413854 2010-021024-10 Details | 2019-01-10 Interventional | 1/2 | 0 | Diclofenac Depression Depression Suic… | Not enough recources. - | |||
| NCT01284335 Details | 2019-01-10 Interventional | 1 | 234 | Docetaxel Erlotinib Hydro… Gemcitabine Temozolomide Neoplasms Advanced Solid … | Study was terminated due to the termination of tasisulam development. This study was terminated early due to termination of development of the tasisulam compound. All participants were considered to have completed the study upon the completion of one cycle of treatment. | |||
| NCT00547443 NCT00975260 Details | 2019-01-10 Interventional | 1/2 | 0 | Carboplatin Paclitaxel Sorafenib Carcinoma, Non-… Lung Neoplasms Lung Cancer | Withdrawn as the sponsor has stopped the drug for NSCLC population - | |||
| NCT03173365 Details | 2019-01-09 Interventional | 2 | 2 | Brimonidine Tar… Hand-Foot Syndr… Syndrome Hand-foot Syndr… | It is no longer practicable to complete the trial - | |||
| NCT02901106 Details | 2019-01-09 Interventional | 4 | 11 | Dimethyl Fumara… Multiple Sclero… Multiple Sclero… Sclerosis | Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow
all the patients, whatever their treatment. - | |||
| NCT02730195 Details | 2019-01-09 Interventional | 2 | 9 | Pioglitazone Tyrosine Kinase… Leukemia Leukemia, Myelo… Leukemia, Myelo… Chronic Myeloge… Recurrent Chron… | - Study was terminated early due to previous principal investigator leaving institution. |